Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
 Conference - EconoTimes)
SAN DIEGO, April 04, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase their scientific expertise at this year’s American Association for Cancer Research’s International Conference (AACR) in Chicago, IL on April 14th – 18th.
CrownBio’s scientists will present more than a dozen scientific posters describing their latest efforts to revolutionize preclinical development of cancer treatments. These scientific posters will demonstrate the combined power of CrownBio’s integrated oncology platform to advance oncology pipelines using their exhaustive patient-derived xenograft (PDX) collection, innovative humanized tumor models and three dimensional ex vivo cultures that recapitulate the in vivo tumor microenvironment. Featured work will show data from novel models that enable precise evaluation of new cancer therapeutics, including bi-specific T-cell engagers (BiTEs), targeted cancer immunotherapies and combinatory immunotherapies.
“I am excited to share Crown Bioscience’s cutting-edge research with colleagues at AACR,” said Dr. Henry Li, Crown Bioscience’s Vice President of Translational Oncology. “The data presented will exhibit the utility of our clinically relevant solutions to identify critical biomarkers and improve preclinical evaluation of cancer therapies.”
“Crown Bioscience is honored to play a leading role in presenting opportunities for scientific advancements at AACR,” said Laurie Heilmann, Chief Business Officer. “The work of our dedicated scientific team exemplifies Crown Bioscience’s commitment to helping researchers solve global health challenges through continued innovation of our scientific translational platform.”
Delegates can request copies of the posters and learn more about Crown Bioscience’s scientific translational platform at booth #3012.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
